Cefdinir: An expanded-spectrum oral cephalosporin

Annals of Pharmacotherapy

Volumn 34, Issue 12, 2000, Pages 1469-1477

  Guay, D R P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cefdinir; Cephalosporin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFACLOR; CEFALEXIN; CEFDINIR; CEFPODOXIME PROXETIL; CEFPROZIL; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; PENICILLIN V;

ANTIMICROBIAL ACTIVITY; COST BENEFIT ANALYSIS; DRUG ABSORPTION; DRUG COST; DRUG DISPOSITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STABILITY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; VAGINITIS;

EID: 0033638210     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19407     Document Type: Review

References (48)

1. FK482, a new orally active cephalosporin: Synthesis and biological properties
2. Morphological alterations of Staphylococcus aureus and Streptococcus pyogenes exposed to cefdinir, a new oral broad-spectrum cephalosporin
3. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem
4. In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem
5. The effects of quinolones on the adherence of type-1 fimbriated Escherichia coli to mannosylated agarose beads
6. The in-vitro activity of cefdinir (FK482), a new oral cephalosporin
7. In vitro activity of cefdinir (FK482, PD134393, CI-983): A new orally active cephalosporin
8. Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines
9. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD 134393), a novel orally administered cephalosporin
10. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients
11. Pharmacokinetics of cefdinir and its transfer to dialysate in patients with chronic renal failure undergoing continuous ambulatory peritoneal dialysis
12. Comparative in vitro activity and β-lactamase stability of FK482, a new oral cephalosporin
13. Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens
14. Cefdinir: In vitro activity study and effect of human serum
15. In vitro antibacterial activity of FK482, a new orally active cephalosporin
16. In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and β-lactamase stability
17. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production
18. Susceptibility testing, interpretive criteria and drug stability for cefdinir, cefetamet, and cefpodoxime against Neisseria gonorrhoeae
19. The sensitivity of clinical bacteria isolated in Scotland to the oral cephalosporin, cefdinir
20. Comparative in-vitro activity of cefdinir against multiresistant Haemophilus influenzae
21. Antimicrobial activity of three investigational cephalosporins (BK-218, cefdinir, and RU29246) against Legionella
22. Antistaphylococcal activity of cefdinir, a new oral third-generation cephalosporin, alone and in combination with other antibiotics, at supra- and sub-MIC levels
23. Post-antibiotic effects of cefdinir on Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pyogenes
24. Bactericidal activity and postantibiotic effect of cefdinir (CI983, FK482) against selected pathogens
25. Stability of cefdinir (CI-983, FK482) to extended-spectrum plasmid-mediated β-lactamases
26. Activities of other β-lactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases
27. Interaction of cefdinir with beta-lactamases
28. Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolates
29. Validation of E test for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices
30. Method development for the determination of cefdinir and its related substances by high-performance liquid chromatography
31. Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses
32. Distribution of cefdinir, a third generation cephalosporin antibiotic, in serum and pulmonary compartments
33. Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients
34. A study of 5-day cefdinir treatment for streptococccal pharyngitis in children
35. Study of the use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients
36. Cefdinir versus amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children
37. Five-day cefdinir treatment for streptococcal pharyngitis
38. Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in the treatment of acute community-acquired bacterial sinusitis
39. Cefdinir versus cephalexin for the treatment of skin and skin-structure infections
40. Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia
41. Efficacy and safety of cefdinir in the treatment of patients with acute bronchitis
42. Antibiotic-associated hemorrhagic colitis without Clostridium difficile toxin in children
43. Cefdinir (CI-983), a new oral amino-2-thiazolyl cephalosporin, inhibits human neutrophil myeloperoxidase in the extracellular medium but not the phagolysosome
44. In vitro activity of two new oral cephalosporins, cefixime and cefdinir (CI983), on human peripheral mononuclear and polymorphonuclear neutrophil functions
45. Cefdinir-mediated modification of the susceptibility of bacteria to the antibacterial activity of human serum and polymorphonuclear neutrophils
46. Impairment of cefdinir absorption by iron ion